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Abstract
Background:  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that plays an
important role in survival signaling. FAK has been shown to be overexpressed in breast cancer
tumors at early stages of tumorigenesis.
Methods: To study the direct effect of FAK on breast tumorigenesis, we developed Tet-ON
(tetracycline-inducible) system of MCF-7 breast cancer cells stably transfected with FAK or
dominant-negative, C-terminal domain of FAK (FAK-CD), and also FAKsiRNA with silenced FAK
MCF-7 stable cell line. Increased expression of FAK in isogenic Tet-inducible MCF-7 cells caused
increased cell growth, adhesion and soft agar colony formation in vitro, while expression of
dominant-negative FAK inhibitor caused inhibition of these cellular processes. To study the role of
induced FAK and FAK-CD in vivo, we inoculated these Tet-inducible cells in nude mice to generate
tumors in the presence or absence of doxycycline in the drinking water. FAKsiRNA-MCF-7 cells
were also injected into nude mice to generate xenograft tumors.
Results: Induction of FAK resulted in significant increased tumorigenesis, while induced FAK-CD
resulted in decreased tumorigenesis. Taq Man Low Density Array assay demonstrated specific
induction of FAKmRNA in MCF-7-Tet-ON-FAK cells. DMP1, encoding cyclin D binding myb-like
protein 1 was one of the genes specifically affected by Tet-inducible FAK or FAK-CD in breast
xenograft tumors. In addition, silencing of FAK in MCF-7 cells with FAK siRNA caused increased
cell rounding, decreased cell viability in vitro and inhibited tumorigenesis in vivo. Importantly,
Affymetrix microarray gene profiling analysis using Human Genome U133A GeneChips revealed
>4300 genes, known to be involved in apoptosis, cell cycle, and adhesion that were significantly
down- or up-regulated (p < 0.05) by FAKsiRNA.
Conclusion: Thus, these data for the first time demonstrate the direct effect of FAK expression
and function on MCF-7 breast cancer tumorigenesis in vivo and reveal specific expression of genes
affected by silencing of FAK.
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Background
Focal adhesion kinase (FAK) is a 125 kDa non-receptor
tyrosine kinase localized at the focal adhesions [1], which
are the contact points between cells and extracellular
matrix and are the sites of intense tyrosine phosphoryla-
tion [2]. FAK is tyrosine phosphorylated in response to a
number of stimuli, including clustering of integrins [3],
plating on fibronectin or collagen [4,5], and in response
to a number of mitogenic agents [6]. FAK is involved in
regulation of different cellular processes, such as cell
spreading, adhesion, motility, proliferation, and survival
[7]. Although several studies supported that FAK plays a
role in breast carcinogenesis [8-11], the direct and specific
role of FAK up and down-regulation on breast cancer tum-
origenesis in vivo and genes expression profiling effected
by FAK silencing are not understood.
FAK was originally identified as a major tyrosine phos-
phorylated protein in cells transformed by v-Src and asso-
ciated with c-Src [12,13]. FAK is overexpressed in invasive
and metastatic tumors [14], and the FAK gene is also
amplified in many types of tumors [15], suggesting a role
for FAK in adhesion or survival in tumor cells. In cancer
cells, attenuation of FAK expression induces detachment
and apoptosis [16], suggesting that a FAK-dependent sig-
nal is required for tumor cell growth. Furthermore, an
activated form of FAK leads to resistance to anoikis [17],
and FAK degradation is associated with apoptosis [18,19].
The C-terminal domain of FAK, called FAK-CD is analo-
gous to murine FAK-related non-kinase (FRNK) [16], and
has been shown to cause increased cell rounding, detach-
ment, and apoptosis when transduced into breast and
colon cancer cells [20-22].
Immunohistochemical analysis of FAK expression dem-
onstrated up-regulation of FAK in 88% of invasive and
metastatic breast tumors [23]. The up-regulation of FAK
occurred at early stages of breast carcinogenesis [24], as
FAK overexpression was detected ductal carcinoma in situ
(DCIS) that precedes tumor cell invasion and metastasis
[25]. FAK overexpression highly correlated with microves-
sel density, metastasis, and angiogenesis [26]. However,
the studies on the role of FAK in breast tumorigenesis in
vivo have been mostly limited to immunohistochemical
studies of tumor biopsies. The recent study using Cre/loxP
recombination system to disrupt FAK function in the
mammary epithelium demonstrated that FAK is required
for the transition of premalignant hyperplasia to carcino-
mas and their subsequent metastasis [27].
To determine the direct role of FAK in breast tumors in
vivo, we created stable clones of human breast cancer cells
overexpressing FAK or dominant-negative FAK-CD using
the Tet-ON system and studied these cells in a nude
xenograft model. In addition, we employed RT-PCR Low-
density Array and Affymetrix analyses to reveal genes
directly affected by FAK up or down-regulation. To the
best of our knowledge, this is the first study of gene
expression profiles affected by FAK regulation in MCF-7
breast cancer cell model.
Methods
Cells
MCF-7 cell line was purchased from ATCC and cultured in
Eagle's minimal essential medium (EMEM) containing
10% fetal bovine serum (FBS), 10 μg/ml insulin, 1 mM
sodium pyruvate, and 0.1 mM nonessential amino acids.
Antibodies, plasmids and reagents
For Western blot analyses, the antibodies used were anti-
FAK 4.47 (Upstate Biologicals), FAK; C-terminal antibody,
C20 (Santa Cruz); HA-tag; P-418-Src, Y118-paxillin, paxil-
lin; AKT; PY397-FAK antibodies were from Biosource Inc,
and anti-β-Actin from Sigma Inc. DMP1 antibody was
obtained from Abcam Inc. Hygromycin and doxycycline
were obtained from Clontech Laboratories, Inc. Geneticin,
G418 was obtained from MP Biomedics Inc. The Tet-ON
gene expression System was obtained from Clontech Labo-
ratories Inc. The Tet-ON system (Clontech Laboratries Inc.)
contained pTet-ON vector, pTRE-2hyg and pTRE-2hyg-
Luc vectors.
Construction of FAK and FAK-CD-TRE-2 plasmids
The HA-tagged FAKcDNA fragment that was subcloned
from pcDNA3 plasmid into BamHI and EcoRV sites of
TRE-2-hyg plasmid. FAK-CD, FAK-C-terminal domain of
FAK (677–1052 amino acids) was obtained by PCR. The
PCR fragment was subcloned into NheI and EcoRV sites of
TRE-2 plasmid. The FAK and FAK-TRE-2 plasmid
sequences were confirmed by sequencing in the ICBR
facility (UF, Shands Cancer Center).
Generation of stable human doxycycline-inducible breast 
cancer MCF-7 cells, overexpressing FAK or dominant-
negative FAK-CD
The first step was to create stably transformed MCF-7 cells
by transfecting with neomycin-resistant pTet-ON regula-
tor plasmid, encoding rtTA protein (reverse tTA, tetracy-
cline-controlled transactivator). The stably transformed
MCF-Tet-ON clones were selected by cultivation in
EMEM, containing 500 μg/ml Geneticin, G418. The Tet-
ON MCF-7 cells were selected and used for transfection of
FAK and FAK-CD-TRE-2-hyg plasmids with Lipofectamin
2000 (Invitrogen Inc) according to the manufacturer's pro-
tocol. The transfected cells with TRE-2-hyg, FAK-TRE-2-
hyg and FAK-CD-TRE-2-hyg plasmids were maintained in
a medium with G418 (0.2 mg/ml) and hygromycin (0.1
mg/ml). The dose- and time-dependent experiments on
stably transfected Tet-ON cells showed a maximal induc-
tion of FAK and FAK-CD at 2 μg/ml doxycycline at 4 daysBMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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of cell cultivation. The pooled population of cells with
maximal induction of FAK and FAK-CD by 2 μg/ml doxy-
cycline used for the study.
Generation of MCF-7 cells stably expressing FAKsiRNA
The pRNAT-H1.4-hyg plasmid was kindly provided by Dr.
K. Brown (University of Florida, Gainesville). For genera-
tion of siRNA construct, the GenScript software was used.
The primers for generating the hairpin construct contain-
ing FAKsiRNA were the following (with siRNA sequences
shown in bold):
FAKsiRNA#1 oligonucleotides were 5'-CGCGTCG-
TAATACTCGCTCCATTGCACCTT GATATCCGGGTGCA
ATGGAGCGAGTATTATTTTTTCCAAC-3' and comple-
mentary oligonucleotide. For FAKsiRNA#2, oligonucle-
otides were the following: 5'-CGCGTCGTA AATGCC
TTGATGTACATCTTTGATATCCGAGATGTAC ATCAAGG
CATTTATTTTT TCCAAC-3' and the complementary oligo-
nucleotide. For control siRNA, scrambled FAK siRNA or
firefly luciferase oligonucleotides were used. Oligonucle-
otides for control siRNA (scrambled FAK siRNA#1
sequence) were generated with GenScript software and
oligonucleotides were the following: 5'-CGCGTCGC
CACTTACGATAGCTCCATTCT TG ATATCCGGAAT-
GGAGCTATCGTAAGTGGTTTTTTCCAAC-3' and the com-
plementary oligonucleotide. Firefly luciferase siRNA was
also used as a control, and the oligonucleotides were 5'-
CGCGTCGTCGAAGTACTCAGCGTAAGTTGATAT CCGC
TTACGCTGAGTACTT CGATTTTTTCCAAC-3' and the
complementary oligonucleotide. The oligonucleotide
duplexes were subcloned into MluI and XhoI sites of
pRNAT-H1.4-hyg plasmid. The resulting siRNA DNAs
were used for transfecting cells with Lipofectamin 2000
(Invitrogen Inc) according to the manufacturer's protocol.
The MCF-7 cells were transfected with control vector, con-
trol siRNA, FAKsiRNA#1, and FAKsiRNA#2 and after sev-
eral weeks growing in the presence of hygromycin (100
μg/ml), stable clones were collected and analyzed by
Western immunoblotting with FAK antibodies. The stable
cell line with highest reduction of FAK expression was
used for the study.
Western Blotting
Western Blotting was performed as described before [28].
Immunohistochemistry staining of xenograft tumors
Tumors from untreated and treated with doxycycline-
treated mice were removed and fixed in 4% formaldehyde
solution immediately after surgical resection. The fixed
samples were analyzed in the Immunohistochemistry
Core Facility (UF, Department of Pathology). FAK stain-
ing was performed, as described previously with FAK 4.47
antibodies [29].
Cell growth in vitro
2 × 105 cells were plated on 6-well plates. Cell growth was
determined by counting cells on hemocytometers. Trypan
blue exclusion assay was used for detecting viable cells.
RNA isolation
Total cellular RNA was isolated from cultured cells with a
NucleoSpin RNA II Purification Kit (Clontech Laboratories,
Inc.) according to the manufacturer's protocol.
Taq Man Low Density Array Real time PCR assay
Customized Taq Man Low density arrays with 44 different
genes (Table 1) and a GAPDH probe as a normalization
control were obtained from Applied Biosystems. The iso-
lated RNA was used for PCR reaction as described in the
manufacturer's protocol. The ABI PRISM 7700 cycler's
software calculated a threshold cycle number (Ct) at
which each PCR amplification reached a significant
threshold level. The relative quantity, RQ, was calculated
and statistical analysis was performed with Student's t-
test.
Microarray and statistical data analyses
RNA was isolated from MCF-7, MCF-7-Vector, MCF-7-
Control luciferase siRNA, FAKsiRNA#1, and FAKsiRNA#2
samples using Clontech Labs, Inc. Kit. The cDNA prepara-
tion, probe labeling, hybridization and image analysis of
the arrays were carried at ICBR Core Facility (UF) accord-
ing to the manufacturer's recommendations (Affymetrix,
Santa Clara, CA, USA), using Affymetrix Human Genome
U133A GeneChip containing 47000 transcripts. For the
data analysis, we treated siRNA#1, siRNA#2 as siRNA
group, and MCF7, MCF-7-Vector and MCF-7-Control
siRNA as control group. We used with 4 replicates per
group in the analysis. Affymetrix Microarray software was
used to analyze the data.
Statistical tests were performed using BioConductor statis-
tical software http://www.bioconductor.org/[30]. Data
pre-processing and normalization were performed using
the Affy package [31]. Raw data were normalized by
Robust Multichip Analysis (RMA) approach. The local
pooled error (LPE) method [32] was applied to detect the
genes which are significant differentially expressed
between FAK siRNA and control (MCF-7-Vector and Con-
trol siRNA) samples, and the resampling technique was
used to control the false-discovery rate (FDR). In combi-
nation with a resampling FDR correction, the LPE method
was shown to outperform other 2-sample comparison
methods [32]. We used local-pooled-error (LPE)
approach to evaluate the level of significance for each
gene's differential expression. The LPE estimation is based
on pooling errors within genes and between replicate
arrays for genes in which expression values are similar.BMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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The p-values from LPE were used as first criteria to define
the significant gene set. The complete data are uploaded
to NCBI website, Accession number GSE11581. Differen-
tially expressed genes were ranked by the p-values, and the
genes with p < 0.05 were considered as differentially
expressed genes at a statistically significant level. For those
significant genes, different level of fold-change were used
to select the significant differentially expressed genes.
Cluster analysis was performed on these selected differen-
tially expressed genes using hierarchical clustering with
the complete linkage method on a similarity matrix built
with Pearson correlation coefficient. The results of the
cluster analysis were displayed at heat map. The data are
deposited in NCBI database (NCBI Accession number
GSE11581).
Soft agar growth assay
Cells cultivated for 6 days with or without doxycycline (2
μg/ml) were plated in 0.3% agar (with or without doxycy-
cline) on the plates, containing 0.5% agar (with or with-
out doxycycline). The plates were cultivated on the plates
for 2–3 weeks. The colonies were counted on stained with
crystal violet plates under the microscope. Samples were
assayed in duplicates.
Adhesion Assay
96-well plates coated with collagen were blocked in 0.5%
BSA in the EMEM medium. Then 2 × 104 of cells were
plated on collagen-treated plates and incubated at 37°C
for 37 minutes in CO2 incubator. Cells were washed with
PBS and fixed with 3.7% formaldehyde for 10 minutes.
After washing with PBS, cells were stained with crystal vio-
let (5 mg/ml in 2% ethanol). Then 2% SDS was added and
plate was read at 590 nm to detect adhesion of cells.
Tumor growth in nude mice
Female nude mice (4–5 weeks old) were ordered from
Harlan Laboratories Inc. All experiments were performed
according to guidelines of the approved IACUC protocol.
To supplement the estrogens for MCF-7 proliferation each
nude mouse was implanted with a 1.5 mg of 17β-estradiol
pellet (Innovative Research of America, Sarasota, FL, USA). A
week after the pellet implantation, 5 × 106 of MCF-7-Tet-
ON cells stably expressing FAK-TRE-2 or FAK-CD were
subcutaneously injected into the mice. Mice were divided
into two groups: the first group did not receive doxycy-
cline in the drinking water, and the second group received
doxycycline (2 mg/ml) in the water. For FAKsiRNA exper-
iments, 5 × 106 of MCF-7 cells were injected subcutane-
ously into mice with implanted 1.5 mg of 17β-estradiol
pellet and tumor growth was observed. The tumors were
measured using calipers and the tumor volume was calcu-
lated using the formula volume, V = L × W2/2, where L-
long diameter and W-short diameter.
Statistical analyses
Student's t test was performed to determine significance.
The difference between data with p < 0.05 was considered
significant.
Results
Doxycycline induces expression of FAK and FAK-CD in 
MCF-7-Tet-ON breast cancer cells
To understand the biologic role of FAK in breast cancer
cells, stable clones overexpressing FAK with a HA-tag were
created from MCF-7 breast cancer cells using the Tet-ON
system. The MCF-7-Tet-ON cells stably expressing FAK or
Table 1: Fold changes of mRNA expression levels in MCF-7-Tet-
ON cell lines cultivated in the presence or absence of 
doxycycline (2 μg/ml) for 6 days
Gene Symbol Dox+/Dox- Ratio
Tre-2 FAK FAK-CD
PTK2 0.59 1.86 * 0.82
PTK2B 0.82 0.85 0.64
p53 0.99 0.66 0.85*
DMTF1 1.20 0.65* 0.81
SRC 1.95 0.76 0.87
MAPK3 1.05 0.74 0.97
AKT1 0.56 0.58 0.73
MAP2K1 0.57 0.52* 0.52
MAPK8 0.70 0.61* 0.85*
FYN 0.84 0.33* 0.65*
CDC2 0.72 1.02 0.82*
CDK4 0.94 0.88* 0.94*
RB1 0.88 0.48* 0.60*
SOCS2 1.12 0.65* 1.20*
SYK 0.66 0.47* 0.63*
CDK2 0.97 0.93* 0.73
CDK3 0.80 0.71 0.74
RAF1 0.78 0.60* 0.54*
ABL1 0.63 0.66 0.78*
TEC 0.67 0.63* 0.58*
PXN 0.96 0.62* 0.75*
SHC1 0.98 0.62* 0.78
BCAR1 0.62 0.53 0.70
MAK2K6 0.76 1.04 1.73*
EPHA1 0.56 0.78 0.75
CTNNB1 0.80 0.56* 0.70*
CHEK1 0.75 0.62* 0.62*
ATM 1.09 0.65 0.99
BIRC5 0.93 0.88 0.74
CDC25C 1.27 1.05 1.18
BCL2 0.31 0.30 0.37
TLN2 0.72 0.81* 0.65*
FLT1 0.33 0.37 0.46
PINK1 1.18 0.51* 0.65*
STAT1 0.70 0.54* 0.46
ARHGEF2 0.75 0.56 0.73
ITGB1 0.46 0.52* 0.65*
CELSR1 1.26 0.88 0.79
LAMC2 0.64 0.38* 0.64*
*p < 0.05, t-test; ** mRNA levels of some genes from Additional file 1 
was not detectableBMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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FAK-CD were cultivated in the presence of doxycycline
and Western blotting was performed with FAK antibodies
(Figure 1). Expression of FAK (Figure 1A) and FAK-CD
(Figure 1B) was induced by doxycycline compared to the
cells without doxycycline. Western blotting analysis with
HA-tag antibody confirmed expression of HA-tagged FAK
(Figure 1A). Doxycycline-induced FAK was activated,
resulting in increased Y397 autophosphorylated FAK and
increased phosphorylation of FAK substrate, Y118-paxil-
lin (Figure 1A).
Doxycycline induces FAK and FAK-CD in MCF-7-Tet-ON cell line Figure 1
Doxycycline induces FAK and FAK-CD in MCF-7-Tet-ON cell line. A, B, MCF-7-Tet-ON stable cell line was gener-
ated with stable expression of FAK (A) or FAK-CD (B). Addition of doxycycline (2 μg/ml) for 6 days resulted in overexpres-
sion of FAK or FAK-CD. Western blotting with HA-tag antibody was performed to detect HA-tagged FAK. Western blotting 
with Y397 antibody shows expression of activated FAK in MCF-7-Tet-ON-FAK cells. Western blotting with 118-Y-paxillin 
antibody demonstrates increased phosphorylation of FAK-substrate paxillin in MCF-7-Tet-ON-FAK cells. Western blotting 
with beta-actin shows equal loading of proteins. C, Exogenous FAK localizes to focal adhesions. MCF-7-Tet-ON-HA-FAK or 
control MCF-7-Tet-TRE-2 cells. Immunostaining with HA-tag antibody was performed to detect HA-tagged FAK. Staining with 
FITC-conjugated phalloidin detected actin in the cells. Dox, doxycyclin. D, Cell rounding and displacement of FAK from the 
focal adhesions in MCF-7-Tet-ON-FAK-CD cells. To detect FAK in the cells, we stained cells for FAK with 4.47 N-terminal 
FAK antibody. Upper panels: MCF-7-Tet-ON-TRE-2 cells, lower panels: MCF-7-Tet-ON-FAKCD cells.
AB
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To determine whether exogenous HA-tagged FAK local-
ized to focal adhesions, immunostaining with HA-tag
antibody was performed. Doxycycline-inducible FAK
mainly localized to the cytoplasm, perinuclear area and
the focal adhesions in MCF-7-Tet-ON-FAK cells (Fig. 1C,
lower panels), while control MCF-7-Tet-ON-TRE-2 cells
were negative by immunostaining with HA-tag antibody
(Figure 1C, upper panels). Induction of FAK with doxycy-
cline did not change stress fiber formation, compared to
the cells without doxycycline, as detected by staining actin
with phalloidin (Figure 1C).
To detect the effect of exogenous FAK-CD on FAK localiza-
tion in cells with doxycycline-inducible FAK-CD overex-
pression, we stained FAK with the N-terminal domain
antibody (Figure 1D). Doxycycline caused displacement
of FAK from the focal adhesion and induced cell rounding
(Figure 1D). To quantify the cell rounding, we counted
the percent of rounded cells caused by doxycycline-induc-
ible FAK-CD (Figure 2A). Rounding in the presence of
doxycycline was induced more than 5 times in the MCF-7
cells overexpressing FAK-CD. In contrast, there was no cell
rounding caused by overexpression of FAK compared to
the TRE-2 stable control cells (Figure 2A). Thus, doxycy-
cline-induced FAK-CD caused changes in cell morphology
resulting in cell rounding.
Doxycycline-inducible FAK increases MCF-7 cell growth, 
adhesion and soft agar colony formation, while FAK-CD 
decreases these cellular processes
MCF-7 cells expressing TRE-2, FAK-TRE-2 or FAK-CD-TRE-
2 were grown without and with doxycycline for 8 days,
and viable cells were counted (Figure 2B). Control MCF-
7-Tet-ON-TRE-2 cells that did not significantly change cell
growth in vitro (Figure 2B). In contrast, cells with doxycy-
cline-inducible FAK expressed significantly (p < 0.05)
increased cell growth at 6–8 days, while cells with induced
FAK-CD had significantly (p < 0.05) decreased cell growth
(Figure 2B). To detect the effect of overexpressed FAK and
FAK-CD on cell adhesion, we plated MCF-7 cells on colla-
gen and performed adhesion assay (Figure 2C). Doxycy-
cline-inducible FAK resulted in induction of cell adhesion
compared to the cells without doxycycline, while FAK-CD
induction resulted in significantly decreased cell adhesion
(Figure 2C).
To detect whether FAK and FAK-CD affected anchorage-
independent growth, cells were treated with doxycycline
(2 μg/ml) for 6 days, resuspended in 0.3% agar, with or
without doxycycline, and cells were cultivated for 3 weeks
on soft agar, and colonies were counted. Doxycycline-
induced FAK resulted in an increased number of colonies
compared to cells without doxycycline, while FAK-CD
resulted in decreased colony formation (Figure 2D).
Thus, overexpression of FAK increases breast cancer cell
growth, adhesion and soft agar colony formation in vitro,
while dominant-negative FAK, FAK-CD decreases these
cellular processes.
Doxycycline-inducible FAK induces tumor growth, while 
doxycycline-inducible FAK-CD reduces the tumor growth 
in nude mice in vivo
To determine role of FAK and FAK-CD in breast tumori-
genesis, we injected MCF-7-Tet-ON-FAK, FAK-CD and
TRE-2-vector stable cell lines into two groups of nude
mice given drinking water either with or without doxycy-
cline and observed tumor growth. Doxycycline-induced
FAK significantly increased tumor volume, more than 2.9
times that of control TRE-2 mice (Figure 3A, upper panel).
Induction of FAK-CD had a 3-fold decreased tumor vol-
ume (Figure 3A, upper panel). A similar result was
observed with tumor weights (Figure 3A, lower panel).
Western blotting with FAK-C-terminal antibody showed
an increased level of FAK and FAK-CD in tumors of doxy-
cycline-treated mice with induced FAK and FAK-CD
expression, respectively (Figure 3B). Thus, induced FAK
expression increased breast tumor growth in mice
xenograft model and FAK-CD decreased tumor growth in
vivo.
TaqMan Low Density Array analysis in Tet-inducible MCF-
7-Tet-ON-FAK cell lines and tumors demonstrates specific 
overexpression of FAK
To determine the molecular mechanism of FAK and FAK-
CD induction, we performed TaqMan low-density array
analysis in Tet-inducible MCF-7 cell lines. We compared
the expression of genes inside each isogenic cell line
grown with and without doxycycline. We compared
expression of 44 genes relative to GAPDH control in all
cell lines (Additional file 1). The expression levels of
expression of 39 genes with detectable mRNA levels that
were differentially affected by Tet-inducible FAK or FAK-
CD-induction are shown in Table 1. Real-time PCR dem-
onstrated an increased 1.9 fold expression of FAK in MCF-
Tet-ON-FAK cells cultivated in the presence of doxycycline
(2 μg/ml) for 6 days (Figure 3C, upper left panel), while
control MCF-7-Tet-ON-TRE-2 and MCF-7-Tet-ON-FAK-
CD cells did not demonstrate increased expression of FAK
mRNA in the presence of doxycycline (Figure 3C, upper
left panel). Expression of the FAK homologue Pyk-2 was
not significantly changed in any of the cell lines in the
presence of doxycycline (Figure 3C, lower left panel). The
RNA level of other genes was not significantly affected by
induction of FAK compared with MCF-7-Tet-ON-TRE-2
and MCF-7-Tet-ON-FAK-CD cells. Interestingly, we found
that cyclin D binding myb-like protein 1 (DMP1; also
called DMTF1) was 1.5 fold decreased (p < 0.05) in MCF-
7-Tet-ON-FAK cells in the presence of doxycycline, andBMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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was not affected in MCF-7-Tet-ON-TRE-2 or MCF-7-Tet-
ON-FAK-CD-expressing cell lines. Thus, increased expres-
sion of FAK is consistent with increased tumorigenesis in
MCF-7-Tet-ON xenograft cells in the presence of doxycy-
cline.
To determine that tumors will have increased expression
of FAK in the case of an induced MCF-7-Tet-FAK model,
we performed the TaqMan Low Density Array PCR analy-
sis in tumors and confirmed increased expression of FAK
in MCF-7-Tet-ON xenografted tumors (Figure 3C, upper
The effect of induced FAK and FAK-CD in MCF-7-Tet-ON cell line on cell growth, rounding, adhesion and soft agar colony  formation in vitro Figure 2
The effect of induced FAK and FAK-CD in MCF-7-Tet-ON cell line on cell growth, rounding, adhesion and soft 
agar colony formation in vitro. A, FAK-CD induction with doxycycline causes increased rounding of MCF-7-Tet-ON cells. 
The ratio of rounded cells cultivated either with doxycycline 2 μg/ml for 6 days or without doxycycline treatment (Dox+/Dox- 
ratio) is shown. Bars show average of three independent field counts ± standard deviations. *, p < 0.05, Student's t-test. B, 
Cells with doxycycline-induced FAK had increased cell growth in vitro, while cells with doxycycline-induced FAK-CD expressed 
decreased cell growth. MCF-7-Tet-ON-TRE-2 control, -FAK or -FAK-CD cells were grown without and with doxycycline for 
1–8 days and the cell number of viable cells detected with trypan blue dye is plotted on the graph. *, p < 0.05, Student's t-test. 
Bars show average ± standard deviations of three independent experiments. C, Cells with doxycycline-induced FAK expressed 
increased cell adhesion on collagen, while cells with induced FAK-CD had decreased adhesion. The doxycycline-induced adhe-
sion is expressed relative to the adhesion of cells without doxycycline. Bars show average ± standard deviations of three inde-
pendent experiments. *, p < 0.05, Student's t-test. D, Cells with doxycycline-induced FAK had increased soft agar colony 
formation, while cells with FAK-CD overexpression had decreased colony formation. The number of soft agar colonies on 
plates with doxycycline is expressed relative to the number of colonies on plates without doxycycline *, p < 0.05, Student's t-
test.
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Doxycycline-induced FAK increases tumorigenesis in xenograft mice model in vivo in contrast to FAK-CD Figure 3
Doxycycline-induced FAK increases tumorigenesis in xenograft mice model in vivo in contrast to FAK-CD. A, 
MCF-7-Tet-ON-TRE-2 control cell line, MCF-7-Tet-ON-FAK and MCF-7-Tet-ON-FAK-CD cells were injected into the nude 
mice. Mice were divided on two groups (n = 5–7) that were given either drinking water without or with doxycycline. Doxycy-
cline significantly increased volume and weight, in mice with injected MCF-7-Tet-ON-FAK cells in contrast to FAK-CD. Bars 
show means ± standard errors. *, p < 0.05, Student's t-test. B, Doxycycline induced FAK expression in xenograft tumors with 
injected MCF-7-Tet-ON-FAK cells and induced FAK-CD expression in case of MCF-7-Tet-ON-FAK-CD. Western blotting 
was performed on tumor lysates with FAK-C20, C-terminal antibody for detecting FAK and FAK-CD. C, TaqMan RT-PCR 
analysis of gene expression in MCF-7-Tet-ON cells and in MCF-7-Tet-ON xenograft tumors. Real-time PCR analysis was per-
formed on breast cancer cell lines MCF-7-Tet-ON-TRE-2, -FAK or -FAK-CD grown for 6 days either without or with doxycy-
clin (2 μg/ml) (left panel) and on tumor samples from these injected cell lines without or with doxycycline (right panel) 
(Materials and Methods). Expression of genes was calculated relative to GAPDH control (RQ) and normalized to MCF-7 cells 
in case of cell lines and relatively to MCF-7-Tet-ON-TRE-2 without doxycycline in case of tumor samples. Bars show means ± 
standard errors of two independent experiments. *p < 0.05, FAK mRNA level in MCF-7-Tet-ON-FAK (+Dox) versus MCF-7-
Tet-ON-FAK(-Dox) samples Student's t-test. Left upper panel: FAK expression in MCF-7-Tet-ON breast cell lines, Right upper 
panel: FAK expression in tumor samples (two tumors for each group was used without doxycycline and with doxycycline). Left 
lower panel: Pyk-2 expression in MCF-7-Tet-ON breast cell lines. Right lower panel: Pyk-2 expression in tumor samples (two 
tumors for each group was used without doxycycline and with doxycycline). D, Immunohistochemical analysis of MCF-7-Tet-
ON tumors. MCF-7-Tet-ON-FAK tumors demonstrate increased FAK expression in the presence of doxycycline. E, 
Decreased expression of DMP1 gene in MCF-7-Tet-ON-FAK tumors in the presence of doxycycline. Upper panel: The Real-
Time PCR analysis by TaqMan array assay on tumor samples. Bars show average ± standard errors of two independent exper-
iments. * p < 0.05, FAK +Dox tumors versus FAK-Dox tumors, Student's t-test. Lower panel: Western with DMP1 antibody 
was performed on tumor cell lysates. DMP1 protein level was significantly lower in MCF-7-Tet-ON-FAK tumors in the pres-
ence of doxycycline compared with MCF-7-Tet-ON-FAK tumors without doxycycline. F, Decreased expression of AKT1 in 
MCF-7-Tet-ON-FAK-CD tumors in the presence of doxyxycline. Western blotting with AKT1 antibody was performed on 
tumor cell lysates, as described above. AKT 1 expression is significantly decreased in MCF-7-Tet-ON-FAK-CD tumors in the 
presence of doxycycline. * p < 0.05, FAK-CD Dox+ tumors versus FAK-CD Dox- tumors, Student's t-test.
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right panel). Tumors with doxycycline-inducible expres-
sion of FAK had significantly increased levels of FAK
mRNA compared with tumors of mice without doxycy-
cline induction and compared with TRE-2 control or
tumors with FAK-CD-induction (Figure 3C, right panel).
Expression of FAK homolog Pyk-2 was not increased and
even was decreased in the MCF-7-FAK tumors in the pres-
ence of doxycycline, and it did not change significantly in
TRE-2 and FAK-CD group in the presence of doxycycline
(Figure 3C, lower right panel). Increased expression of
FAK mRNA observed in the presence of doxycycline in
Tet-ON-FAK-tumors was consistent with increased FAK
protein level demonstrated by Western blotting (Figure
3B) and by immunohistochemical staining (Figure 3D).
Among the genes, specifically affected by FAK or FAK-CD
overexpression in the presence of doxycyclin, we found
that the DMP1 mRNA expression was > 1.7 fold decreased
(p < 0.05) in MCF-7-Tet-ON-FAK tumors grown in the
presence of doxycycline, and the difference was not signif-
icant in case of TRE-2-control or FAK-CD tumors (Figure
3E, upper panel). Decreased expression of DMP1 protein
in MCF-7-Tet-ON-FAK tumors grown in the presence of
doxycycline was confirmed by Western blotting (Figure
3E, lower panel). In the case of MCF-7-Tet-ON-FAK-CD
tumors that were grown in the presence of doxycycline,
the level of AKT1 mRNA decreased >1.3 fold (p < 0.05),
while the difference was not significant in MCF-7-Tet-ON-
TRE-2 or MCF-7-Tet-ON-FAK tumors The same result was
obtained by Western blotting with AKT antibody (Figure
3F). The AKT1 expression was decreased in MCF-7-Tet-
ON-FAK-CD tumors that were grown in the presence of
doxycycline (Figure 3F).
Thus, increased tumorigenesis was observed in the tumors
with MCF-7-Tet-ON-FAK cells and decreased tumorigene-
sis was observed in the case of expression dominant-neg-
ative FAK inhibitor FAK-CD.
FAK siRNA causes cell rounding, decreases cell growth in 
vitro and inhibits tumorigenesis in vivo
To test the effect of decreased FAK expression and com-
pare with the FAK-CD-induced expression, we generated
stable MCF-7 cell lines, expressing vector alone, Control
siRNA, FAKsiRNA#1 and FAKsiRNA#2. All stably trans-
fected cells were GFP-positive showing effective expres-
sion of protein, since vector had GFP-tag. Western
blotting with FAK antibody demonstrates that both FAK-
siRNA #1 and #2 cells efficiently decreased expression of
FAK in MCF-7 cells, while MCF-7, MCF-7-Vector or MCF-
7-Control siRNA did not decrease FAK expression (Figure
4A). FAKsiRNA caused change in cell morphology and sig-
nificantly increased cell rounding compared with MCF-
Vector or Control siRNA (Figure 4B). In addition, FAK-
siRNA significantly decreased cell growth in vitro com-
pared with MCF-7, Vector and Control siRNA cells (Figure
4C). Thus, FAK siRNA caused cell rounding and decreased
cell growth in vitro.
To test the effect of down-regulated FAK on tumorigene-
sis, we injected MCF-7, MCF-7-Vector, MCF-7-Control
siRNA, MCF-7-FAKsiRNA and FAKsiRNA#2 cells in the
nude mice and observed tumor growth. Both FAKsiRNA
#1 and #2 decreased tumor cell growth compared to MCF-
7 and MCF-7-Vector and MCF-7-Control siRNA cells (Fig-
ure 5A, left upper panel). The significantly decreased
tumor size in case of FAK siRNA#1 and #2 is shown on
Figure 5A, right panels. Both FAK siRNA #1 and #2 signif-
icantly decreased tumor volume versus control MCF-7,
MCF-7-Vector and MCF-7-Control siRNA cells (Figure 5A,
left lower panel). We performed analysis of FAK expres-
sion in these tumor samples by Western blotting (Figure
5B). Tumors from both FAKsiRNA#1 and FAKsiRNA#2
had significantly decreased FAK expression compared
with tumors from MCF-7, MCF-7-Vector and MCF-7-Con-
trol siRNA group (Figure 5B). Thus, down-regulation of
FAK by FAK siRNA significantly decreased tumor growth
in vivo compared to MCF-7 and MCF-7-Vector and MCF-
7-Control siRNA cell lines.
Affymetrix Microarray and TaqMan Low-Density RT-PCR 
array assays reveal more than 4300 genes down- and up-
regulated in MCF-7-FAKsiRNA cell lines
In addition, to better understand molecular mechanism
of FAK down-regulation by FAKsiRNA, we performed
gene expression of MCF-7, MCF-7-Vector, MCF-7-Control
siRNA, FAKsiRNA#1 and FAKsiRNA#2 cell line samples
by microarray analysis using Affymetrix Human Genome
U133 GeneChip Array, covering the whole human
genome with >47000 transcripts. Among all genes on the
Chips, we revealed over than 4300 genes (all gene pro-
files, affected by FAKsiRNA are downloaded to NCBI data-
bases with [Accession number GSE11581]) were
significantly with p < 0.05 either up- or down-regulated in
FAKsiRNA#1 and FAKsiRNA#2 cell lines versus control
group (MCF-7, MCF-7-Vector, MCF-7-Control siRNA cell
lines). The heatmap of 4300 genes that were significantly
down-regulated and up-regulated (p < 0.05) by FAKsiRNA
in MCF-7 cells is shown on Figure 5C.
169 genes were more than 2-fold down or up-regulated (p
< 0.05), 32 genes were more than 3-fold down- or up-reg-
ulated (p < 0.05), and 12 genes were > 4-fold (p < 0.05)
affected by FAKsiRNA. We found that expression of FAK
was 1.5-fold down-regulated (p < 0.05) in the pooled
FAKsiRNA#1 and FAKsiRNA#2 group compared to con-
trol group (Table 2). TaqMan Real-time PCR array assay
demonstrated the same 1.5 fold decrease of FAKmRNA by
both FAKsiRNA compared to control MCF-7 and MCF-7-
Vector cells, confirming and validating microarray data.BMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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Importantly, Pyk2 and several other genes were not signif-
icantly different by both microarray and Real-time-PCR,
additionally validating both methods.
Among genes that were significantly (p < 0.05) down-reg-
ulated by both FAKsiRNA#1 and FAKsiRNA#2 versus con-
trol (MCF-7, MCF-7-Vector and MCF-7-Control siRNA)
group were PEG10, Paternally expressed 10 gene; AREG,
Amphiregulin; insulin-like growth factor binding protein
5; MAP2K5, Mitogen-activated protein kinase 5 (Table 2).
Among genes significantly up-regulated (p < 0.05) by
both FAKsiRNA#1 and #2 versus control group were
TXNIP, thioredoxin interacting protein (>3.2 fold);
TFAP2A, transcription factor AP-2 (5 fold) (Table 2). Sev-
eral of the genes were > 4–6 times either down-regulated
(such as WISP2, CDH11) or up-regulated (TFAP2A,
HINT3, ZNF738 and KIT) (p < 0.05) by FAKsiRNA. (Table
2). In addition, we performed Affymetrix analysis on
FAKsiRNA significantly decreased FAK and caused MCF-7 cell rounding and decreased cell growth in vitro and tumorigenesis in  vivo Figure 4
FAKsiRNA significantly decreased FAK and caused MCF-7 cell rounding and decreased cell growth in vitro and 
tumorigenesis in vivo. A, Western blotting demonstrates that FAKsiRNA#1 and FAKsiRNA #2 decreased expression of 
FAK in MCF-7 cells, while Control siRNA and Vector control samples did not affect FAK expression. B, FAKsiRNA causes 
increased cell rounding. GFP-positive MCF-7, MCF-7-Vector, MCF-7-Control siRNA and FAKsiRNA#1 and #2 cell lines with 
rounded morphology (shown on right panels) were counted on three separate fields with 100 cells counted per field. The aver-
age percent of rounding is shown ± standard errors. *, p < 0.05, FAKsiRNA versus control samples. C, FAKsiRNA caused 
decreased cell growth in vitro. MCF-7, MCF-7-Vector, MCF-7-Control (luciferase) siRNA and FAKsiRNA#1 and #2 cells were 
plated on a 6-well plate, cultivated for 1, 4, 6 and 8 days were and counted on hemocytometer with trypan blue for detection 
of viable cell growth. FAKsiRNA#1 and #2 significantly decreased cell growth compared to control MCF-7, MCF-7-Vector or 
Control siRNA cells. *, p < 0.05 FAKsiRNA#1 and FAKsiRNA#2 versus control cells.
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MCF-7-Tet-ON-FAK cells, cultivated either with doxycy-
cline (2 μg/ml) for 6 days or without doxycycline. We
revealed 510 genes that are up- or down-regulated in
MCF-7-Tet-ON-FAK with induced FAK (p < 0.05) (all gene
profiles, affected by FAK-induction in MCF-7-Tet-ON-FAK
cells are downloaded to NCBI databases with [Accession
number GSE11581]). There were several genes that were
inversely regulated in MCF-7-Tet-ON-FAK cells, cultivated
either in the presence of doxycycline (2 μg/ml) or without
doxycycline, and in MCF-7-FAKsiRNA cells. Some genes
were down-regulated in MCF-7-Tet-ON-FAK cells with
induced FAK and increased in MCF-7 cells with silenced
Decreased tumorigenesis in vivo and gene expression analysis in MCF-7-FAKsiRNA model Figure 5
Decreased tumorigenesis in vivo and gene expression analysis in MCF-7-FAKsiRNA model. A, Upper left panel, 
MCF-7, MCF-7-Vector, MCF-7-Control siRNA (firefly luciferase siRNA), MCF-7-FAKsiRNA#1 and FAKsiRNA#2 were 
injected into mice, and tumor volume was measured at different time points (1–30 days). FAKsiRNA #1 and #2 decreased 
tumor growth in vivo compared to MCF-7, MCF-7-Vector and MCF-7-Control siRNA cells. Bars show means of tumor growth 
measured at day 30 ± standard errors (n = 5 mice in each group). Lower left panel: Tumors from FAKsiRNA cells had signifi-
cantly less weight than tumors from control MCF-7, MCF-7-Vector and MCF-7-Control siRNA group (measured at day 30). *, 
p < 0.05 FAKsiRNA#1 and FAKsiRNA#2 versus control cells. Right panel: Representative tumor sizes are shown from each 
group. B, Tumors collected at day 30 from MCF-7-FAKsiRNA mice express decreased levels of FAK. Western blotting was 
performed with FAK antibody. C, Profile of gene expression in FAKsiRNA cell lines with Affymetrix gene Chips. Microarray 
heat map of genes on MCF-7 cell lines is shown. Upregulated genes (green) and down-regulated (Red). Affymetrix gene Chip 
Human Genome U133A (two chips per sample) was used. More than 4300 genes (shown) up or down-regulated with p < 0.05 
in FAKsiRNA#1 and FAKsiRNA#2 pooled group compared to MCF-7, MCF-7-Vector and MCF-7-Control siRNA pooled 
group.
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FAK, such as TXNIP that was 2.7-fold (p < 0.05) decreased
in MCF-7-Tet-ON-FAK cells (Dox+/Dox- ratio = 0.36) com-
pared to increased in FAKsiRNA cells (Table 2); IFI27
(interferon, alpha-inducible protein 27) was significantly
decreased in MCF-7-Tet-ON-FAK cells (Dox+/Dox- ratio =
0.6) compared to 2.2-fold induction by FAKsiRNA cells;
CD36 (CD36 molecule (thrombospondin receptor)) was
significantly down-regulated in MCF-7-Tet-ON cells
(Dox+/Dox- ratio = 0.360, while it was 2.4-fold up-regu-
lated in MCF-7-FAKsiRNA cells. In contrast, other genes,
such as IGFBP5 and STK4 (Table 2) were significantly up-
regulated in MCF-7-Tet-ON-FAK cells in the presence of
doxycycline and down-regulated in MCF-7-FAKsiRNA
cells. In summary, FAKsiRNA decreased FAK expression
and tumorigenesis in vivo, and Affymetrix gene expression
analysis revealed more than 4300 genes that are up- and
down-regulated by FAK siRNA, that are critical for study-
ing molecular mechanisms of down-stream FAK signaling
during breast tumorigenesis in vivo.
Discussion
FAK controls survival and is activated at the early stages of
breast carcinogenesis [25]. FAK expression was demon-
strated in ductal carcinoma in situ (DCIS) tumors. The
study suggested that FAK overexpression occurred in pre-
invasive, DCIS tumors preceding tumor metastasis. In
addition, we have shown that FAK formed a protein com-
plex with vascular endothelial receptor-3 protein, VEGFR-
3 in breast cancer cells [33] suggesting its critical role in
breast lymphogenesis and angiogenesis.
Thus, in the present study we performed analysis of
induced FAK expression and induced dominant-negative
FAK, FAK-CD in breast carcinogenesis using MCF-7-Tet-
ON model. We generated MCF-7-tet-inducible cells, sta-
bly transfected with Tet-inducible FAK or Tet-inducible
FAK-CD plasmids and performed analysis of this induced
expression on the cellular processes in vitro and tumori-
genesis in vivo. Increased expression of FAK increased cell
growth, adhesion and soft agar colony formation in vitro.
In contrast, induced expression of FAK-CD decreased
these cellular processes. We inoculated these cells in nude
mice and demonstrated increased tumorigenesis in the
case of induced FAK and reverse processes in the presence
of induced FAK-CD. Expression of FAK-CD caused cell
rounding, which is explained by exogenous localization
of FAK-CD in the focal adhesion and displacement of FAK
from the focal adhesion sites [20]. The data are consistent
with our previous report, where we have shown that exog-
enous FAK-CD can inhibit FAK functions and cause cell
rounding and apoptosis of BT474 breast cancer cells [34].
FAK-CD or FRNK has been shown to decreased cell motil-
ity of AU-565 breast cancer cells [35]. In this report, we for
the first time analyzed the direct effect of FAK and FAK-CD
Tet-inducible expression on gene expression and cellular
processes in MCF-7 line and in breast xenograft models.
The increased tumorigenesis was accompanied by
increased FAK mRNA and protein levels. Real-time PCR
analysis demonstrated specific increased FAK mRNA in
MCF-7-Tet-ON-FAK cells. Importantly, the expression of
homologous Pyk-2 was not increased and was even
decreased in MCF-7-Tet-ON-FAK cells indicating FAK-
independent regulation of Pyk-2 in MCF-7 cells.
Although, the recent report demonstrated increased
expression of Pyk-2 and FAK in tissues from early and
advanced breast cancers suggesting importance of Pyk-2
pathway in breast tumorigenesis [10], the down-stream
signaling mediated by FAK and Pyk-2 kinases is different.
The functional differences between Pyk-2 and FAK kinases
are supported by the recent report on the structural differ-
ences between C-terminal FAT domains of FAK and Pyk-2
and differences in association and phosphorylation of
focal adhesion protein, paxillin [36]. In this study we
show that silencing of FAK with two different FAKsiRNA
in MCF-7 stable cell line resulted in decreased breast tum-
origenesis in vivo and decreased FAK expression in the
tumor samples. We revealed significant differences in
gene expression affected by FAK silencing or FAK up-regu-
lation in MCF-7 cells. Thus, FAK is critical for breast cell
survival and tumorigenesis. The models can be used for
targeted therapy and for studies of FAK inhibitors.
Intriguingly, MCF-7-Tet-ON-FAK cell line and tumors
grown in the presence of doxycycline had decreased
DMP1 (cyclin D binding protein 1) mRNA and protein
levels. DMP1 is a transcription factor which binds to cyc-
lin D and when overexpressed induces cell cycle arrest
[37]. DMP1 can bind Arf1 (p14Arf known as an inhibitor
of Mdm-2 and stabilizer of p53) promoter and activate its
transcription, thus regulating Arf-p53 pathway. It is
known that loss of DMP1 caused spontaneous tumorigen-
esis in mice and death by 24 months of age from different
forms of cancer [38]. Dmp1-/- mice among phenotypic
abnormalities had also poor mammary development
[37]. The Dmp1+/- tumors often retain wild type allele of
DMP1, thus DMP1 is haplo-insufficient for tumor sup-
pression [37]. Overexpression of cyclin D1, which is
found to be overexpressed in 60–80% of breast cancer
tumors, inhibits the transcriptional activity of DMP1 and
antagonizes its function [37]. It was shown that overex-
pression of FAK increased expression of cyclin D1 [39],
which contributed to increased expression of cellular pro-
liferation. The function of human DMP1 protein (the
transcription factor that is involved in the oncogene-
tumor suppressor signaling) is an unexplored area in
human cancer, and it remains to discover its post-transla-
tional modifications and identification of DMP1-protein
binding partners [37]. Thus, FAK-DMP1-cyclin D1 linked
pathway can be a novel mechanism regulating intracellu-
lar functions and carcinogenesis, and decreased DMP1BMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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Table 2: Several sets of Up-regulated and Down-regulated genes (p < 0.05) after FAK silencing with FAKsiRNA*
Down-regulated genes
Probeset ID Gene Symbol Gene name Gene Ontology (GO) Biological 
process
Fold change siRNA/Control
212094_at PEG10 Paternally expressed 10 Proteolysis; apoptosis; differentiation 0.22
205239_at AREG Amphiregulin Cell-cell signaling; proliferation 0.23
223062_s_at PSAT1 Phosphoserine Aminotransferase 1 L-serine biosynthetic; metabolic; 
amino-acid biosynthetic processes
0.29
214467_at GPR65 G protein-coupled receptor 65 Apoptosis; G-protein coupled receptor 
protein signaling pathway; immune 
response
0.31
238695_s_at RAB39B RAB39B, member RAS oncogene 
family
Transport; small GTPase mediated 
signal transduction; protein transport
0.39
239014_at CCAR1 Cell division cycle and apoptosis 
regulator 1
Apoptosis; cell cycle; cell division 0.42
231879_at COL12A1 Collagen, type XII, alpha 1 Skeletal development; phosphate 
transport; cell adhesion; collagen fibril 
organization
0.44
203424_s_at IGFBP5 Insulin-like growth factor binding 
protein 5
Regulation of cell growth; signal 
transduction
0.49
235412_at ARHGEF7 Rho guanine nucleotide exchange 
factor (GEF)7
Regulation of Rho protein signal 
transduction; intracellular signaling 
cascade
0.52
216765_at MAP2K5 Mitogen-activated protein kinase 
kinase 5
Protein amino acid phosphorylation; 
signal transduction
0.61
223746_at STK4 Serine/threonine kinase 4 Cell morphogenesis; protein amino 
acid phosphorylation; apoptosis kinase 
cascade
0.65
1559529_at PTK2 PTK2 protein tyrosine
kinase 2
Protein amino acid phosphorylation; 
integrin-mediated signaling pathway; 
signal complex assembly
0.68
205397_x_at SMAD3 SMAD family member 3 SMAD protein complex assembly; 
regulation of transcription from RNA 
polymerase II promoter
0.70
Up-regulated genes
204214_s_at RAB32 RAB32, member RAS oncogene 
family
Small GTPase mediated signal 
transduction; Protein transport
1.52
204794_at DUSP2 Dual specificity phosphatase 2 Inactivation of MAPK activity; Protein 
amino acid dephosphorylation
1.86
206898_at CDH19 Cadherin 19, type 2 Cell-cell adhesion; cell adhesion 2.42
201117_s_at CPE Carboxypeptidase E Neuropeptide signaling pathway; Insulin 
processing; metabolic process
2.64
205749_at CYP1A1 Cytochrome P450, family 1, 
subfamily A, polypeptide 1
Dibenzo-p-dioxin metabolic process;
oxidation reduction
2.97
201010_s_at TXNIP Thioredoxin interacting protein Transcription; cell cycle; keratinocyte 
differentiation
3.26
232306_at CDH26 Cadherin-like 26 Cell adhesion 4.05
205792_at WISP2 WNT1 inducible signaling pathway 
protein 2
Cell growth; adhesion; signal 
transduction
4.09
207173_x_at CDH11 Cadherin 11, type 2, OB-cadherin 
(osteoblast)
Skeletal development; adhesion; 
ossification
4.12
204653_at TFAP2A Transcription factor AP-2 alpha Transcription; signal transduction 4.99
228697_at HINT3 Histidine triad nucleotide binding 
protein 3
Signal transduction 5.33
229700_at ZNF738 Zinc finger protein 738 Regulation of transcription 8.7
205051_s_at KIT v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog
Protein amino acid phosphorylation; 
signal
Transduction; epithelial proliferation
12.59
* The complete set of genes down-regulated or up-regulated by FAKsiRNA with p < 0.05 are up-loaded to NCBI database (NCBI Accession 
number GSE11581).BMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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expression can explain the increased cellular growth and
tumorigenesis of the MCF-7-Tet-ON-FAK model.
Similar to adenoviral expression of FAK-CD that caused
increased apoptosis [20,28], Tet-inducible MCF-7-Tet-
ON-FAK-CD cells showed decreased viability and growth
on soft agar. Interestingly, TaqMan analysis demonstrated
significantly decreased AKT level in MCF-7-Tet-ON-FAK-
CD tumors. These data are consistent with our previous
report, when adenoviral FAK-CD decreased AKT in breast
cancer cell lines [28]. We have shown that AKT increased
survival of the breast cancer cell line [28]. Thus, down-reg-
ulation of AKT by doxycycline-induced FAK-CD can
explain decreased tumorigenesis in these tumors.
We demonstrated that silencing of FAK with two FAK
siRNA decreased tumorigenesis in MCF-7 xenograft
model that was accompanied by decreased FAK expres-
sion in tumor samples. Importantly, we performed
Affymetrix chip microarray analysis and for the first time
demonstrated more than 4300 genes significantly up- and
down-regulated, and >160 genes that are >2-fold down or
up-regulated (p < 0.05) in FAKsiRNA#1 and #2 samples
group compared to control group that provides basis for
future mechanistic detail study of FAKsiRNA-directed
gene expression in breast cancer cells. The most important
that both microarray data and TaqMan Real-time PCR
array data demonstrate significantly decreased expression
of FAK in FAKsiRNA cell lines compared to the control
group, and these data together with decreased tumorigen-
esis in vivo support the critical role of FAK signaling in
breast tumorigenesis.
The data on 169 genes that were 2-fold significantly up or
down-regulated by FAKsiRNA in MCF-7 breast cancer
model provide a basis for detail mechanistic study of FAK
down-stream signaling during breast tumorigenesis. Sev-
eral genes that were up-regulated by FAKsiRNA, like
MAP2K5, mitogen-activated protein are connected with
the FAK signaling pathway. We have shown that FAK up-
regulated ERK1/2 in the stress conditions [28] in breast
cancer cells. MAP2K5 (MEK5) kinase has been shown to
be correlated with metastasis in prostate tumors [40] and
has been involved in breast carcinogenesis[41]. Other
important genes down-regulated by both FAKsiRNA#1
and #2 was PEG10, paternally expressed 10 gene that is
directly involved in tumorigenesis [42]. PEG10 is a c-Myc
target gene in cancer cells and has been shown to be acti-
vated during breast tumorigenesis, expressed in 55% of
ductal carcinoma in situ and 32% of invasive ductal carci-
noma [43]. Thus, down-regulation of PEG10 by FAK-
siRNA is consistent with decreased tumorigenesis in these
cells. Another important gene that was down-regulated by
FAKsiRNA is PSAT1, phosphoserine aminotransferase.
Recently, it has been shown that PSAT1 overexpression
stimutated cell growth of colon cancer cells [44]. High
PSAT1 mRNA levels were associated in breast cancers with
poor clinical response to endocrine therapy [45]. Thus,
PSAT1 functions as pro-survival and proliferative factor in
tumorigenesis.
Among up-regulated genes (>3-fold) by FAKsiRNA was
thiredoxin interacting protein (TXNIP) that is known to
be involved in apoptosis [46]. In pancreatic Miapaca-2
cells, overexpression of TXNIP resulted in increased basal
apoptosis and increased sensitivity to cisplatin and oxali-
platin [46]. We also performed Affymetrix array analysis
on Tet-ON-FAK MCF-7 cells and found that thiredoxin
interacting protein (TXNIP) was 2.7 fold decreased in the
presence of doxycyline, supporting that TXNIP is regu-
lated by FAK and plays role in breast tumorigenesis. We
revealed several genes that were inversely regulated in
MCF-Tet-ON-FAK with induced FAK and in MCF-7 cells
with silenced RNA, 16 genes were >1.5 fold in inversely
regulated, p < 0.05 (not shown), providing a basis for the
mechanism of their regulation. Another gene that was ~5
fold up-regulated by FAKsiRNA is transcription factor AP-
2 alpha (TFAP2A). Activation and expression of AP-2 was
associated with increased apoptosis and inhibiton of cell
growth [47]. In addition, immunohistochemical staining
studies showed that loss of transcription factor AP-2 cor-
related with disease progression from normal breast to
invasive breast cancer disease [48]. Another group dem-
onstrated that reduced expression of AP-2 transcription
factor associated with aggressive breast cancer [49].
Down-regulation of AP-2 with siRNA led to enhanced
breast cancer tumor growth and reduced chemotherapy-
induced cell death [50]. Thus, these few examples of
down-regulated and up-regulated genes can explain
reduced tumorigenesis in FAKsiRNA MCF-7 model and
suggest that FAKsiRNA can be used as a therapy approach.
The presented Tet-regulated FAK-CD, dominant negative
FAK, breast cancer cell model can be compared with Tet-
inducible dominant-negative c-Src model [51]. Similar to
dominant-negative c-Src-induced model of Tet-ON MCF-
7 cells, cells with induced FAK-CD had decreased cell
adhesion and viability and reduced tumorigenesis, con-
sistent with our data on cooperative survival signaling of
FAK and Src in colon cancer cells [22].
Conclusion
In conclusion, we have shown for the first time that Tet-
inducible FAK increased cell growth, adhesion and soft
agar colony formation in vitro, while it increased breast
tumorigenesis in vivo. In contrast, Tet-inducible FAK-CD
and FAKsiRNA blocked these processes in vivo. TaqMan
Low Density Array identified several specific genes
affected by modulation of FAK expression and function,
such as DMP1 and AKT1. In addition, Affymetrix analysisBMC Cancer 2009, 9:280 http://www.biomedcentral.com/1471-2407/9/280
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revealed more than 4300 genes that were affected by FAK-
siRNA in MCF-7 xenograft tumors. This system demon-
strates the basis for future studies on the role of FAK and
downstream signaling in breast tumorigenesis and the
biology of breast cancer cells. Thus, FAK is a promising tar-
get for future breast cancer therapy.
List of abbreviations
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